Ose Immunotherapeutics annual debt-to-equity ratio
2020
2021
2022
2023
2024
2025
Ose Immunotherapeutics Debt-to-Equity Ratio Growth & History (OSE)
Ose Immunotherapeutics's debt-to-equity ratio was 1.27 for fiscal 2025.
View full Ose Immunotherapeutics company overviewOse Immunotherapeutics annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 1.27 | 0.55 | +76.29% |
| 2024 | 2024-12-31 | 0.72 | −1.27 | −63.74% |
| 2023 | 2023-12-31 | 1.99 | 0.62 | +45.34% |
| 2022 | 2022-12-31 | 1.37 | 0.60 | +76.89% |
| 2021 | 2021-12-31 | 0.78 | 0.46 | +143.83% |
| 2020 | 2020-12-31 | 0.32 | — | — |
Ose Immunotherapeutics quarterly debt-to-equity ratio
Q4.24
Q4.25
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | 1.27 | 0.55 | +76.29% |
| Q4 2024 | 2024-12-31 | 0.72 | — | — |
Ose Immunotherapeutics debt-to-equity ratio trends
Over the last five fiscal years, Ose Immunotherapeutics's debt-to-equity ratio increased from 0.32 to 1.27, a change of 0.96. The latest reported quarter, Q4 2025, shows 1.27.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ose Immunotherapeutics source filings ↗